Title

應用蛋白質體學技術鑑定肺癌新腫瘤標記

Translated Titles

Proteomics-based Identification of Novel Biomarkers in Lung Cancer

Authors

蘇美淑

Key Words

免疫治療法 ; 二維電泳分析 ; 西方墨點法 ; MALDI-TOF質譜儀 ; Immunotherapy ; 2D-SDS-PAGE ; western blot ; MALDI-TOF-MS ; β-actin ; Wnt-8a

PublicationName

臺北醫學大學醫學檢驗暨生物技術學系所學位論文

Volume or Term/Year and Month of Publication

2004年

Academic Degree Category

碩士

Advisor

李宏謨

Content Language

繁體中文

Chinese Abstract

在數位參與台灣國家衛生院免疫治療法 ( Immunotherapy ) 之癌症末期病人中,有一位病人獲得顯著的緩解。本研究乃針對該免疫療法成功之肺癌末期患者案例,利用蛋白質體學配合西方墨點法來探測免疫療法引發的體液免疫所產生之特異性抗體的可能抗原。 我們以患者在接受免疫法治療前與治療77天後所採得之血清做為免疫前及免疫後抗體,以A549腺肺癌細胞株培養後萃取細胞蛋白質做為癌細胞抗原,經過2D-SDS-PAGE蛋白質分析後,以西方墨點法研究肺癌患者治療前、治療後所產生的抗體在識別A549腺肺癌細胞所萃取之細胞蛋白質有何不同。我們發現肺癌患者在治療77天後所獲之恢復期血清可辨識四個A549腺肺癌細胞萃取液之特殊蛋白質點,經過一連串蛋白質塊切割,膠內酵素切割萃取蛋白質成分,再經高效能MALDI-TOF質譜儀分析,透過NCBI蛋白質資料庫比對得知此四個蛋白質點分別是β-actin 、 Human Interferon-induced protein with tetratricopeptide repeats 2 (IFIT-2) 、 keratin與Wnt-8a等四個蛋白質。 本研究之結果顯示經進一步研究後,這四個蛋白質將可能當作新的癌症生物指標,亦可嘗試發展成為癌症疫苗之用。

English Abstract

Several end stage lung cancer patient have been recruited to accept newly developed immunotherapy in a NHRI clinical trial project. One of the subjects revealed remarkable remission after immunotherapy. We hypothesized that the immunotherapy has elicited both cellular and humeral immune responses. In the present study, we used a proteomic approach to identify proteins that induce a humeral immune response in lung cancer after immune therapy. Two-dimensional polyacrylamide gel electrophoresis ( 2-D PAGE ) was used to separate several thousand cellular proteins in A549 lung cancer cells. Separated proteins are transferred onto membranes and immuno blot with sera obtained from patient before immunotherapy and 77 days post immunotherapy using Western blot analysis. Proteins that differentially react with the post-immune serum ( but not with pre-immnue sera ) were identified and excised. Four candidate protein spots were identified and subjected to in-gel digestion and matrix assisted laser desorption ionization — time of flight ( MALDI-TOF ) analysis. Our data revealed that ?-actin, human interferon-induced tetratricopeptide repeats 2 ( IFIT 2 ) , keratin and Wnt 8a were potential tumor antigens that elicited humeral immune response in the clinical trial initiative. Thus, these proteins can be considered as potential tumor markers that can be used in clinical laboratory. Furthermore, these results may be used in future development of tumor-vaccine.

Topic Category 醫藥衛生 > 基礎醫學
醫學科技學院 > 醫學檢驗暨生物技術學系所
Reference
  1. 2. Alaiya AA, Franzen B, Auer G, Linder S. Cancer proteomics: from identification of novel markers to creation of artifical learning models for tumor classification. Electrophoresis. 2000 ;21(6):1210-7. Review.
    連結:
  2. 3. Baker SG. Identifying combinations of cancer markers for further study as triggers of early intervention. Biometrics. 2000;56(4):1082-7.
    連結:
  3. 4. Banks RE, Dunn MJ, Forbes MA, Stanley A, Pappin D. The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis--preliminary findings. Electrophoresis. 1999;20(4-5):689-700.
    連結:
  4. 5. Boyes DA. The value of a Pap smear program and suggestions for its implementation. Cancer. 1981 ;48(2 Suppl):613-21.
    連結:
  5. 7. Caprioli RM, Farmer TB, Gile J. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal Chem. 1997 ;69(23):4751-60.
    連結:
  6. 11. Connor RJ, Prorok PC, Weed DL. The case-control design and the assessment of the efficacy of cancer screening. J Clin Epidemiol. 1991 ;44(11):1215-21.
    連結:
  7. 13. Craven RA, Totty N, Harnden P, Selby PJ, Banks RE. Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis: evaluation of tissue preparation and sample limitations. Am J Pathol. 2002 ;160(3):815-22.
    連結:
  8. 14. Cronin KA, Weed DL, Connor RJ, Prorok PC. Case-control studies of cancer screening: theory and practice. J Natl Cancer Inst. 1998 ;90(7):498-504. Review.
    連結:
  9. 15. Cuzick J, Szarewski A, Terry G, Ho L, Hanby A. Human papillomavirus testing in primary cervical screening. Lancet. 1995 ;345(8964):1533-6.
    連結:
  10. 16. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S. The case for early detection. Nat Rev Cancer. 2003 ;3(4):243-52. Review.
    連結:
  11. 18. Franzen B, Hirano T, Okuzawa K, Uryu K, Alaiya AA. Sample preparation of human tumors prior to two-dimensional electrophoresis of proteins. Electrophoresis. 1995 ;16(7):1087-9.
    連結:
  12. 19. Fung ET, Wright GL Jr, Dalmasso EA. Proteomic strategies for biomarker identification: progress and challenges. Curr Opin Mol Ther. 2000 ;2(6):643-50. Review.
    連結:
  13. 20. Gohagan JK, Prorok PC, Hayes RB, Kramer BS; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials. 2000 ;21(6 Suppl):251S-272S.
    連結:
  14. 21. Gorg A, Obermaier C, Boguth G, Harder A, Scheibe B. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis. 2000 ;21(6):1037-53. Review.
    連結:
  15. 22. Hanash SM. Biomedical applications of two-dimensional electrophoresis using immobilized pH gradients: current status. Electrophoresis. 2000 ;21(6):1202-9. Review.
    連結:
  16. 23. Henschke CI, Naidich DP, Yankelevitz DF, McGuinness G, McCauley DI. Early lung cancer action project: initial findings on repeat screenings. Cancer. 2001 ;92(1):153-9.
    連結:
  17. 24. Henschke CI. Early lung cancer action project: overall design and findings from baseline screening. Cancer. 2000 ;89(11 Suppl):2474-82.
    連結:
  18. 25. Herbert B. Advances in protein solubilisation for two-dimensional electrophoresis. Electrophoresis. 1999 ;20(4-5):660-3. Review.
    連結:
  19. 26. Iqbal S, Lenz HJ. Targeted therapy and pharmacogenomic programs. Cancer. 2003 ;97(8 Suppl):2076-82. Review.
    連結:
  20. 27. Kim JH, Skates SJ, Uede T, Wong Kk KK, Schorge JO. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA. 2002 ;287(13):1671-9.
    連結:
  21. 28. Kiviat NB, Critchlow CW. Novel approaches to identification of biomarkers for detection of early stage cancer. Dis Markers. 2002 ;18(2):73-81. Review.
    連結:
  22. 30. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002 ;288(14):1749-57.
    連結:
  23. 31. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC. Initial sequencing and analysis of the human genome. Nature. 2001 ;409(6822):860-921.
    連結:
  24. 32. Le Naour F, Brichory F, Misek DE, Brechot C, Hanash SM. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics. 2002 ;1(3):197-203.
    連結:
  25. 34. Link AJ. Multidimensional peptide separations in proteomics. Trends Biotechnol. 2002 Dec;20(12 Suppl):S8-13. Review.
    連結:
  26. 35. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem. 2002 ;48(8):1296-304.
    連結:
  27. 36. Lueking A, Horn M, Eickhoff H, Bussow K. Protein microarrays for gene expression and antibody screening. Anal Biochem. 1999 ;270(1):103-11.
    連結:
  28. 37. Mahadevia PJ, Fleisher LA, Frick KD, Eng J, Goodman SN. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA. 2003 ;289(3):313-22.
    連結:
  29. 38. McIntosh MW, Pepe MS. Combining several screening tests: optimality of the risk score. Biometrics. 2002 ;58(3):657-64.
    連結:
  30. 39. Monardo PJ, Boutell T, Garrels JI, Latter GI. A distributed system for two-dimensional gel analysis. Comput Appl Biosci. 1994 ;10(2):137-43.
    連結:
  31. 40. National cancer institute. Surveillance Epidemiology and Result program (in line). http://seer.cancer.gov/. 2002.
    連結:
  32. 41. O’Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem. 1975 ;250(10):4007-21.
    連結:
  33. 42. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer. 1993 ;54(4):594-606.
    連結:
  34. 43. Pepe,M.S. etal. Phases of biomarker development for early detection of cancer. Nature. 2001 ;412: 822-826.
    連結:
  35. 44. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002 ;359(9306):572-7.
    連結:
  36. 45. Petricoin EF 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst. 2002 ;94(20):1576-8.
    連結:
  37. 46. Pollak MN, Foulkes WD. Challenges to cancer control by screening. Nat Rev Cancer. 2003 ;3(4):297-303. Review.
    連結:
  38. 47. Ransohoff DF. Cancer. Developing molecular biomarkers for cancer. Science. 2003 ;299(5613):1679-80.
    連結:
  39. 49. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A. 1995 ;92(25):11810-3.
    連結:
  40. 50. Shields JM, Rogers-Graham K, Der CJ. Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. J Biol Chem. 2002 ;277(12):9790-9.
    連結:
  41. 51. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer. 2002 ;2(3):210-9. Review.
    連結:
  42. 52. Simpson RJ, Dorow DS. Cancer proteomics: from signaling networks to tumor markers. Trends Biotechnol. 2001 ;19(10 Suppl):S40-8. Review.
    連結:
  43. 53. Srinivas PR, Kramer BS, Srivastava S. Trends in biomarker research for cancer detection.Lancet Oncol. 2001 ;2(11):698-704. Review.
    連結:
  44. 54. Srinvas PR, Verma M, Zhao Y, Srivastava S. Proteomics for cancer biomarker discovery. Clinical Chemistry. 2002:;48(8):1160-1169.
    連結:
  45. 55. Stoler MH. HPV for cervical cancer screening: is the era of the molecular pap smear upon us? J Histochem Cytochem. 2001 ;49(9):1197-8.
    連結:
  46. 56. Sullivan Pepe M, Etzioni R, Feng Z, Potter JD, Thompson ML. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001 ;93(14):1054-61. Review.
    連結:
  47. 57. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis. 1997 ;18(11):2071-7.
    連結:
  48. 58. Verma M, Srivastava S. New cancer biomarkers deriving from NCI early detection research. Recent Results Cancer Res. 2003 ;163:72-84; discussion 264-6.
    連結:
  49. 59. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ. The sequence of the human genome. Science. 2001 ;291(5507):1304-51.
    連結:
  50. 60. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A. 2003 ;100(6):3410-5.
    連結:
  51. 61. Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst. 1993 ;85(21):1748-51.
    連結:
  52. 62. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer. 2003 ;3(4):267-75. Review.
    連結:
  53. 64. Alan B. Weitberg. Cancer of The Lung. From molecular biology to treatment guidelines. Humana Press, New Jersey, 2002: 81-102.
    連結:
  54. 1. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 2002 ;62(13):3609-14.
  55. 6. Brichory F, Beer D, Le Naour F, Giordano T, Hanash S. Proteomics-based identification of protein gene product
  56. 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res. 2001;61(21):7908-12.
  57. 8. Celis JE, Celis P, Ostergaard M, Basse B, Lauridsen JB. Proteomics and immunohistochemistry define some of the steps involved in the squamous differentiation of the bladder transitional epithelium: a novel strategy for identifying metaplastic lesions. Cancer Res. 1999 ;59(12):3003-9.
  58. 9. Chakravarti DN, Fiske MJ, Fletcher LD, Zagursky RJ. Mining genomes and mapping proteomes: identification and characterization of protein subunit vaccines. Dev Biol (Basel). 2000 ;103:81-90. Review.
  59. 10. Chen G, Gharib TG, Huang CC, Thomas DG, Shedden KA. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res. 2002 ;8(7):2298-305.
  60. 12. Elena A. Shestakova, Jeffrey Wyckoff, Joan Jones, Robert H. Singer, and John Condeelis Correlation of ß-Actin Messenger RNA Localization with Metastatic Potential in Rat Adenocarcinoma Cell Lines. Cancer Res. 1999 ;59: 1202-1205.
  61. 17. Eurekah Bioscience Collection http://www.ncbi.nlm.nih.gov
  62. 29. Kobayashi R. A proteomics approach to find a new breast cancer-specific antigenic marker. Clin Cancer Res. 2001 ;7(11):3325-7.
  63. 33. Le Naour F, Misek DE, Krause MC, Deneux L, Giordano TJ. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res. 2001 ;7(11):3328-35.
  64. 48. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev. 2000 ;9(9):945-51.
  65. 63. Wulfkuhle JD, Sgroi DC, Krutzsch H, McLean K, McGarvey K. Proteomics of human breast ductal carcinoma in situ. Cancer Res. 2002 ;62(22):6740-9.
Times Cited
  1. 何叔孋(2009)。癌症基因治療相關發明專利之研究。國立臺灣大學法律學研究所學位論文。2009。1-99。